The QualityStocks Daily Friday, January 24th, 2020

Today's Top 3 Investment Newsletters

QualityStocks (INND) +125.00%

NetworkNewsWire (PBIO) +80.45%

StocksToBuyNow (BTDG) +60.61%

The QualityStocks Daily Stock List

Casa Minerals, Inc. (CASXF)

Streetwise Reports, Barchart, The Prospector News, Junior Mining Network, Mining Stock Education, Stockwatch, GuruFocus, iresourcenetwork, Resource World, TradingView, Dividend.com, Stockhouse, TMXmoney, and Wallet Investor reported earlier on Casa Minerals, Inc. (CASXF), and we also highlight the Company, here at the QualityStocks Daily Newsletter.

Casa Minerals, Inc. engages in the acquisition, exploration, as well as development of mineral properties situated in Canada. It owns a 100 percent interest in the polymetallic Pitman and Keaper properties. It also has an option to acquire a 75 percent interest in the Arsenault VMS Property. Incorporated in 2007, Casa Minerals has its head office in Vancouver, British Columbia. The Company lists on the OTC Markets.

The Pitman Property consists of seven contiguous mineral tenures encompassing 5,506 hectares. This Property is situated 20 kilometers north of Terrace, British Columbia. The mineral claims of the Pitman Property include a number of historic prospects. These prospects include the Pitman copper-molybdenum ± silver prospect and the Gold Dome and Paddy Mac gold- base metal prospects. Work is continuing on the Pitman Property with a focus on further sampling to better define the distribution of gold, copper, silver and molybdenum values.

The polymetallic Keaper Property is situated 20 kilometers northeast of Terrace, British Columbia. This Property consists of 3,790 hectares. The Keaper Project was first sampled by the B.C. Geological Survey in 2008. Casa Minerals has since carried a number of exploration programs. The latest soil, rock and geological surveys in 2018 identified the rough and yet to be extended Nelson Prospect.

Casa Minerals’ Arsenault VMS Property consists of three mineral tenures encompassing roughly 2,751 hectares positioned in the Atlin Mining Division, British Columbia. In recent years, Casa has conducted several exploration programs on the Arsenault Property. The Company believes that an attractive volcanogenic massive sulphide exploration target may be located within its limits.

In October 2019, Casa Minerals announced the completion of the inaugural drilling program on its 100 percent owned Pitman property near Terrace, British Columbia. The 2,037 meter drill program included both primary prospects of the Pitman Property, Golden Dragon and Dragon Tale.

The second part of the Drill program was targeted at the Dragon Tale prospect where in 2018 Casa Minerals’ reconnaissance work and sampling discovered mixed sulphide mineralization with significant silver, zinc, copper and lead values. Initial work had ascertained that mineralization extends over greater than 600 meters.

Casa Minerals, Inc. (CASXF), closed Friday's trading session at $0.0585, even for the day, on 11,000 volume. The average volume for the last 3 months is 727 and the stock's 52-week low/high is $0.056710001/$0.12449.

chart

Manganese X Energy Corp. (SNCGF)

Resource World, Bull Market News, Geology for Investors, Simply Wall St, Investing News, Market Screener, Mining Stock Education, InvestorIntel, Oil & Gas 360, The Prospector, Ahead of the Herd, StreetWise Reports, Stockwatch, Wallet Investor, Stockhouse, 4-Traders, and Canadian Insider reported beforehand on Manganese X Energy Corp. (SNCGF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Manganese X Energy Corp.’s mission is to acquire and advance high potential manganese mining prospects in North America. The Company’s intention is to supply value added materials to the lithium ion battery and other alternative energy industries. The Company previoulsy went by the name Sunset Cove Mining, Inc. It changed its corporate name to Manganese X Energy Corp. in December of 2016. Manganese X Energy is headquartered in Saint-Laurent, Quebec.

Manganese dioxide is an important element in the manufacture of the most promising types of Lithium Ion batteries. These kinds of batteries are the most promising because of their superior storage capacity, safety, as well as cost.

Manganese X Energy’s plan is to provide a secure ethically sourced manganese supply through exploring and developing its manganese rich deposit near Woodstock, New Brunswick (Battery Hill Project). The Battery Hill property comprises 55 claims totaling 1,228 hectares positioned in Carlton County, New Brunswick. This project incorporates all or part of five manganese zones - Iron Ore Hill, Moody Hill, Sharpe Farm, Wakefield and Maple Hill.

Manganese X Energy also has its Peter Lake Property. Peter Lake comprises 34 claims totalling about 1985 ha positioned in the Mont-Laurier Terrane, in the Central Grenville Province, Quebec. Two Copper-Nickel-Cobalt Occurrences called Peter Lake North and Peter Lake South are included within this Property.

Previous grab sampling returned values ranging from 0.4 percent to 22.8 percent copper, 0.14 percent to 0.73 percent nickel, 500 ppm to 0.266 percent cobalt, and also elevated gold and silver.

Manganese X Energy plans to conduct an exploration program on Peter Lake, with a complete compilation of historic geological work, followed by line cutting, ground geophysics, geology/prospecting, trenching and possible diamond drilling in the future. Special attention during the exploration program will be targeted at the cobalt and possible gold-platinum-palladium potential of the Property.

This past October, Manganese X Energy announced that it received an encouraging update from Kemetco Research, Inc. who is developing a commercializable flow sheet to produce ultra high-purity (more than 99.9 per cent) battery-grade manganese for the increasing electric vehicle (EV) and energy storage sectors. As earlier disclosed from Manganese X’s Battery Hill property in New Brunswick, a 99.60 percent MnSO4 product has been produced. The goal of this phase of the project is to further enhance the purity and produce sufficient samples for marketing purposes.

Manganese X Energy Corp. (SNCGF), closed Friday's trading session at $0.07, even for the day, on 5,000 volume. The average volume for the last 3 months is 1,904 and the stock's 52-week low/high is $0.041799999/$0.133000001.

chart

Paramount Resources Ltd. (PRMRF)

Zacks, Capital Cube, Macrotrends, SmarterAnalyst, Street Insider, Market Seat, TipRanks, Market Wire News, MarketWatch, Investors Hangout, Nasdaq, Market Screener, Investing.com, InvestorsHub, Wallet Investor, GuruFocus, Morningstar, TMXmoney, 4-Traders, MarketBeat, News Scanner, and Stockhouse reported previously on Paramount Resources Ltd. (PRMRF), and we highlighting the Company as well, here at the QualityStocks Daily Newsletter.

Paramount Resources Ltd. is a leading independent energy company centered on responsibly developing its world-class portfolio of varied resource plays. The Company explores for, develops, produces and markets natural gas, oil and natural gas liquids in Alberta, British Columbia, Saskatchewan and the Northwest Territories. Paramount Resources has daily production now nearing 100,000 Boe/d since the acquisition of Apache Canada Ltd. and the merger with Trilogy Energy Corp. Operating in Canada since 1976, Paramount Resources is based in Calgary, Alberta.

The Company has secured significant land positions in what is proving to be the most liquids-rich (and therefore economic) windows of the Montney and Duvernay. It notes that a large set of high rate of return assets at various stages in the development lifecycle provides considerable optionality.

Montney wells at Karr exhibit strong production rates and condensate yields with the 4-24 pad averaging gross peak 30-day production per well of 2,027 Boe/d (339 Bbl/MMcf). Processing and takeaway capacity is in place to support Montney growth at Karr.

This week, Paramount Resources announced that it was notified by Keyera Corp. on January 17, 2020 of an electrical failure within the Keyera Wapiti Gas Plant. The failure resulted in an unplanned outage. Keyera advised Paramount Resources that it expects the Plant to be repaired and resume operations within about two weeks.

Paramount is monitoring the situation closely. The Company will provide more updates if necessary in the event that the outage extends for a duration that causes a material impact to Paramount Resources. The Wapiti asset is a continuation of Karr. Wapiti is characterized by multi-interval potential in the Montney. Karr and Wapiti together have the potential to produce annual free cash flow of $350 MM - $500 MM. Regarding the Wapiti asset, all eleven wells started-up on the Wapiti 9-3 pad had a cumulative average wellhead CGR of 336 Bbl/MMcf.

Paramount Resources Ltd. (PRMRF), closed Friday's trading session at $5.00, up 0.401606%, on 2,610 volume with 20 trades. The average volume for the last 3 months is 8,943 and the stock's 52-week low/high is $3.63000011/$7.42000007.

chart

Peeks Social Ltd. (PKSLF)

OTC Markets, InvestorX, StockInvest.us, Cantech Letter, Central Charts, Investing.com, Wallet Investor, Seeking Alpha, Stockwatch, 4-Traders, Barchart, YCharts, Stockhouse, TradingView, and InvestorsHub reported previously on Peeks Social Ltd. (PKSLF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Peeks Social Ltd.’s chief activity is the development of social media and social commerce products and services for use by consumers and businesses. The Company’s emphasis is on mobile (iOS and Android) products. It engages in the development and marketing of mobile video and livestreaming social media products under the Peeks Social brand. The Company’s shares trade on the OTC Markets Group’s OTCQB. Peeks Social has its corporate office in Toronto, Ontario.

As of this month, Peeks Social has launched its Peeks Reboot 2020 marketing program. This marketing program includes an email based user reactivation program, targeting inactive users and broadcasters. In addition, it includes an affiliate marketing program, which permits approved agents to recruit new users for the Peeks platform.

Affiliate marketers are paid a commission on the platform fees charged to broadcasters. Peeks Social has increased its minimum platform fees from 24 percent to 30 percent for new users. This is to offset the cost of commissions payable to affiliate marketers.

Furthermore, Peeks Social has completed the development of its subscription services. Subscription services will enable users to pay a monthly subscription to broadcaster channels. The addition of subscription services allows Peeks Social to compete with other subscription-based services, including Only Fans and Patreon.

Mr. Rick Padulo, Chief Marketing Officer of Peeks Social, said, “Peeks is now [a] marketing driven company. Our team is now laser focused on providing the industry’s best customer service. As such our app rating has increased from 2.2 stars to over 4 stars on average in our major markets, which has led to an increase in both users and usage. Simply stated our job is to efficiently grow our broadcaster/user base and efficiently keep them engaged longer. I’m excited about our Peeks Reboot 2020 initiatives and the impact they will have on our brand and company.”

Peeks Social Ltd. (PKSLF), closed Friday's trading session at $0.0555, even for the day, on 33 volume with 1 trade. The average volume for the last 3 months is 4,438 and the stock's 52-week low/high is $0.0031/$0.090899996.

chart

Spring Bank Pharmaceuticals, Inc. (SBPH)

Zacks, BioPharmCatalyst, StockNews, Stock Twits, US Post News, TipRanks, The Online Investor, MacroTrends, Central Charts, ETF.com, Simply Wall St, Stockhouse, Investors Observer, Morningstar, Market Chameleon, Stockwatch, YCharts, and Investing.com reported earlier on Spring Bank Pharmaceuticals, Inc. (SBPH), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Spring Bank Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company listed on the NasdaqCM. It is developing novel therapeutics for the treatment of viral infections, inflammatory diseases, as well as certain cancers. Spring Bank’s lead product candidate is inarigivir. The Company previously went by the name Spring Bank Technologies, Inc. It changed its name to Spring Bank Pharmaceuticals, Inc. in May of 2008. Established in 2002, Spring Bank Pharmaceuticals has its corporate headquarters in Hopkinton, Massachusetts.

In essence, the Company engages in the discovery and development of a novel class of therapeutics utilizing its proprietary small molecule nucleotide platform. It designs its compounds to selectively target and modulate the activity of specific proteins implicated in different disease states.

Spring Bank Pharmaceuticals’ inarigivir is undergoing development for the treatment of chronic hepatitis B virus (HBV). The design of inarigivir is to activate within hepatic cells retinoic acid-inducible gene 1 (RIG-I) that has been shown to inhibit HBV viral replication and induce the intracellular interferon signaling pathways for antiviral defense.

Inarigivir is undergoing development as a simple, safe, and also selective oral immunomodulator for inclusion in a combinatorial treatment of hepatitis B. In addition, Spring Bank is developing its lead STING agonist product candidate, SB 11285. This is an immunotherapeutic agent for the treatment of selected cancers.

Regarding the Company’s science, its proprietary small molecule nucleic acid hybrids (SMNH) chemistry platform produces a class of compounds designed to selectively target and modulate the activity of specific proteins implicated in different disease states. The design of its SMNH compounds are to resemble naturally occurring nucleotides and nucleic acids in the body. They act directly on target proteins. As a result, they can be used to upregulate or downregulate the activity of disease-related proteins.

Recently, Spring Bank Pharmaceuticals announced that it stopped dosing and enrolling patients in its Phase 2b CATALYST trials that are examining the use of inarigivir soproxil 400mg for the treatment of chronic hepatitis B virus (HBV). Furthermore, Spring Bank has stopped dosing and enrollment in all other studies of inarigivir in subjects with chronic HBV.

Mr. Martin Driscoll, President and Chief Executive Officer of Spring Bank Pharmaceuticals, said, “We stopped dosing and enrolling patients out of an abundance of caution based on laboratory data from virally-suppressed patients in the CATALYST 2 trial. We are certainly disappointed to stop our current Phase 2 inarigivir trials, but ensuring patient safety and care is of paramount importance to us. Working with the members of our Data Safety Monitoring Board, clinical trial investigators and external experts, we will review all of the information available to us from the CATALYST 2 trial and all other inarigivir trials at the 400mg dose to determine the appropriate path forward for these trials.”

Spring Bank Pharmaceuticals, Inc. (SBPH), closed Friday's trading session at $1.84, off by 8.9109%, on 208,532 volume with 715 trades. The average volume for the last 3 months is 304,877 and the stock's 52-week low/high is $1.16999995/$11.2498998.

chart

Till Capital Corporation (TILCF)

Zacks, Investing.com, MarketWatch, Market Screener, TradingView, All Stocks Today, TipRanks, Nasdaq, MacroTrends, Investors Observer, TMXmoney, Stockhouse, Wallet Investor, Morningstar, and Dividend Investor reported beforehand on Till Capital Corporation (TILCF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Till Capital Corporation owns Omega General Insurance Company. Omega is a Canadian insurance company offering innovative and customized insurance industry solutions, including fronting and run-off services for insurers/reinsurers, within the Canadian market. Furthermore, Omega Insurance Holdings, Inc. operates Focus Group, Inc. Focus is a consulting and project management company servicing the local and worldwide needs of its Property Casualty Insurance clients. Incorporated in 2012, and a Bermuda-domiciled enterprise, Till Capital is based in Hamilton, Bermuda.

Managed by Till Management Company, Mr. William A. Lupien, the Chief Investment Officer, oversees and directs the investment portfolio of Till Capital. Longer term equity investment is augmented by short term trading in an array of financial instruments. On the whole, via its subsidiaries, Till Capital engages in the insurance and reinsurance business in Canada, Bermuda, and the USA. The Company provides assumption reinsurance to insurance companies that want to exit the Canadian market; and to insurance companies that want to transfer their remaining claim liabilities on particular books of business.

In addition, Till Capital acts as the principal insurer and direct writer for insurance companies seeking Canadian business, but lacking the appropriate Canadian insurance licenses; and ongoing and one-time consulting services in the areas of taxation, risk management, mergers and acquisitions (M&As), expert witness testimony, and claim reviews.

Omega General’s main source of revenue is from incoming Canadian branch offices in “run off.” Omega General earns a premium on such portfolio transfer transactions above the transferring company’s claim liabilities. The second area of Omega General’s underwriting areas is a direct insurance premium business. Omega General typically purchases reinsurance for its portfolio transfer and direct insurance premium businesses.

Omega General is regulated by the Canadian Government’s Office of the Superintendent of Financial Institutions (OSFI). OSFI generally expects property and casualty insurance companies to maintain at least a 150 percent minimum capital test, which calculates capital adequacy.

Established in 1985, Focus Group has been providing management and consulting services to the insurance industry for over 25 years. Focus has substantial experience and expertise in managing the operations of foreign insurance companies wishing to operate in Canada without establishing a fully-staffed Canadian operation. Focus provides management services to Omega General and a total range of consulting and management services to other clients.

At present, Focus Group has chief agency contracts with four foreign insurers and management contracts with two foreign insurers. Currently, Focus is Chief Agent in Canada for Groupama S.A.; Pavonia Life Insurance Company of Michigan; Protective Insurance Company; and Virginia Surety Company, Inc.

Till Capital Corporation (TILCF), closed Friday's trading session at $1.30, even for the day, on 2 volume with 1 trade. The average volume for the last 3 months is 1,075 and the stock's 52-week low/high is $0.0313/$2.1400001.

chart

Todos Medical Ltd. (TOMDF)

Penny Stock Hub, Macroaxis, Stock Day Media, Stock News Now, OTC Markets, TradingView, GlobeNewswire, TalkMarkets, Morningstar, PM360Online, InvestorsHub, Investors Hangout, OTC.Watch, Wallet Investor, Market Screener, Stockopedia, Proactive Investors, Stockhouse, and Market Wire News reported earlier on Todos Medical Ltd. (TOMDF), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Todos Medical Ltd. focuses on the development of blood tests for the early detection of cancer and neurodegenerative disorders, including Alzheimer's disease (AD). A clinical-stage in-vitro diagnostic company, it does so through Breakthrough Diagnostics, Inc., its joint venture (JV) with Amarantus Bioscience Holdings, Inc. Breakthrough Diagnostics is developing the Alzheimer’s blood diagnostic LymPro Test®. Todos Medical’s two cancer screening tests are TM-B1 and TM-B2. OTCQB-listed, Todos Medical has its corporate headquarters in Rehovot, Israel.

The Company has developed two cancer screening tests founded on TBIA (Todos Biochemical Infrared Analyses). This is a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. The proprietary and patented method incorporates biochemistry, physics, as well as signal processing.

Todos Medical’s TBIA platform represents a cost effective, scalable, and patient friendly screening method for cancer screening. The TBIA method is a proprietary method for the screening of solid tumours utilizing peripheral blood spectroscopy analysis. The process involves observing the immune system’s response to tumor presence instead of looking for the tumor cells themselves or specific markers. TBIA analyzes the whole biochemical signatures spectrum (including proteins, lipids, nucleic acids and carbohydrates) of effected immune cells from peripheral blood, using infrared spectroscopy.

Todos Medical’s two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. The Company’s new cancer test will add a layer to presently available cancer screening and diagnostics. Its technology is a platform. Todos Medical is investigating methods for using its platform on other kinds of cancers. Initially, the Company is centered on breast and colon cancers.

Earlier this month, Todos Medical announced that it entered into an exclusive option agreement to acquire Provista Diagnostics, Inc. Provista is an in vitro diagnostics company with a CLIA/CAP certified lab in Alpharetta, Georgia, developing and commercializing the proprietary Videssa® blood test for breast cancer. Videssa has been clinically validated for the early and accurate detection of breast cancer based on data from more than one thousand patient samples.

Moreover, Todos Medical at the same time announced that it appointed Mr. Gerald Commissiong, a U.S.-based executive, as Chief Executive Officer (CEO). The Company also announced that it appointed Mr. Daniel Hirsch, an Israeli-based executive of American descent, as Chief Financial Officer. Mr. Commissiong and Mr. Hirsch will facilitate the relocation of Todos Medical from Israel to the USA so that Todos can focus its development and commercialization efforts of its proprietary TBIA cancer diagnostic platform in the USA. Todos Medical’s former CEO, Dr. Herman Weiss, will remain with the Company as Chairman of the Board.

Todos Medical Ltd. (TOMDF), closed Friday's trading session at $0.035, up 16.6667%, on 428,298 volume with 16 trades. The average volume for the last 3 months is 112,367 and the stock's 52-week low/high is $0.028/$0.340000003.

chart

Sunshine Biopharma, Inc. (SBFM)

Stockwatch, Investing.com, Real Investment Advice, Trading View, Market Screener, GuruFocus, Stockopedia, Insider Financial, Simply Wall St, Dividend Investor, Wallet Investor, All Stocks, InvestorsHub and Stockhouse reported earlier on Sunshine Biopharma, Inc. (SBFM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Sunshine Biopharma, Inc. is a pharmaceutical company listed on the OTC Markets. The Company concentrates on the development of drugs for the treatment of aggressive types of cancer. Furthermore, Sunshine offers generic pharmaceuticals, Essential Brand dietary supplements, and certified analytical chemistry services. Sunshine Biopharma has its corporate office in Pointe-Claire, Quebec.

The Company operates by way of three subsidiaries. These comprise Atlas Pharma, Inc. (Testing Services); Sunshine Biopharma Canada, Inc. (Generic Drugs); and NOX Pharmaceuticals, Inc. (Propriety Drugs). Atlas Pharma offers certified testing services of pharmaceutical and other industrial samples. Generic drugs coming soon from Sunshine Biopharma Canada (not available in the U.S.) include SBI-Anastrozole for treatment of Breast Cancer; SBI-Letrozole for treatment of Breast Cancer; SBI-Bicalutamide for treatment of Prostate Cancer; and SBI-Finasteride for treatment of BPH (Benign Prostatic Hyperplasia).

Regarding Sunshine Biopharma’s Proprietary Drugs in development, the Company’s flagship anticancer drug is Adva-27a. This is a GEM-difluorinated C-glycoside derivative of Podophyllotoxin, targeted for different kinds of cancer. The expectation is that Adva-27a will enter Phase I clinical trials for pancreatic cancer and multidrug resistant breast following completion of the GMP manufacturing and formulation of a 2-kilograms quantity for injection.

Sunshine Biopharma also has its dietary supplements product line - Essential 9™. This product contains all 9 essential amino acids in one tablet for maintaining and building muscle mass. In December of 2018, Sunshine Biopharma completed the development of Essential 9™. On December 14, 2018, Health Canada issued NPN 80089663 through which it authorized the Company to manufacture and sell the Essential 9™ product.

In December 2018, Sunshine Biopharma announced it signed an agreement with Crocus Laboratories Inc., (Montreal) for assistance in the manufacturing of Adva-27a. Crocus will help Sunshine Biopharma in the development of a large-scale process for the manufacturing of 2 to 5 kilograms of Adva-27a. The material, which will ultimately be generated by a contract manufacturing organization, will be used for animal toxicity studies and clinical trials.

Recently, Sunshine Biopharma announced it launched 7 new dietary supplements in addition to its original product, Essential 9™. The new products are BCAA; L-Carnitine; L-Creatine; L-Glutamine; Vitaminax; Omega 3; and Vitamin B12.

Sunshine Biopharma, Inc. (SBFM), closed Friday's trading session at $0.0003, up 46.3415%, on 7,382,352 volume with 9 trades. The average volume for the last 3 months is 12,737,328 and the stock's 52-week low/high is $0.000199999/$0.029999999.

chart

Maverick Technology Solutions (MVRK)

OTC Markets, Penny Stock Hub, Biz Journals, News to Watch, OTC.Watch, Research Pool, Investors Hangout, Stockopedia, Stockhouse, Trading View, Wallet Investor, GlobeNewswire and InvestorsHub reported earlier on Maverick Technology Solutions (MVRK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Maverick Technology Solutions is the manufacturer of the highly acclaimed ROSINBOMB™ line of extraction presses and technology. The Company has more than three years operating history developing and producing the ROSINBOMB™ line of rosin presses and accessories for extracting organic concentrates. ROSINBOMB presses necessitate no chemicals or additional hardware to operate. Maverick Technology Solutions is headquartered in Phoenix, Arizona. Maverick lists on the OTC Markets.

The Company established as a family enterprise with deep roots in creating press technology for the organic fruit and vegetable juice market. ROSINBOMB presses are plug and play out of the box. The technology utilizes granted patent and patent pending techniques to optimize extraction processes and permit the user the ability to easily produce naturally-extracted, organic concentrates.

ROSINBOMB presses are manufactured to be the premier quality presses available today. The Company’s stainless steel, fully electric and patent-pending technology delivers 5,000+ lbs of pressure. The design is to ensure the highest possible yield.

This past February, Maverick Technology Solutions announced that its patent pending products are now available through Walmart. The entire product line is prominently featured on Walmart.com. Maverick’s extraction presses and related accessories, most notably the ROSINBOMB Rocket, have been met with critical acclaim. The year 2018 saw the Rocket being named a top ten product by Forbes, the “Best Portable Rosin Press” by Herb, and one of the “Top Holiday Gifts Over $200” by Leafly.

Recently, Maverick Technology Solutions announced the naming of Mr. Douglas Leighton as Chairman of its Advisory Board. Mr. Leighton is Founder and Principal Partner of Altar Rock Capital, (previously Dutchess Capital). He has managed an investment portfolio of more than $2 billion in transactional value. Mr. Leighton was appointed to the Maverick Technology Solutions Advisory Board as Chairmen to help guide the company through the next chapter of its growth and success.

Maverick Technology Solutions (MVRK), closed Friday's trading session at $1.50, up 50.00%, on 6,355 volume with 11 trades. The average volume for the last 3 months is 1,598 and the stock's 52-week low/high is $0.569999992/$2.00.

chart

Bespoke Extracts, Inc. (BSPK)

Simply Wall St, Stockopedia, InvestorsHub, Wallmine, Stockhouse, Ventureline, GuruFocus, Investors Hangout, Barchart, Wallet Investor, Infront Analytics, YCharts, Market Screener, Morningstar, Market Exclusive, Marketwired, Insider Financial, and MarketWatch reported earlier on Bespoke Extracts, Inc. (BSPK), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Bespoke Extracts, Inc. is a producer of high quality, flavorful, hemp-derived cannabidiol (CBD) extract products. The Company established in early 2017 to introduce a proprietary line of premium quality, all-natural CBD products in the form of tinctures and capsules for the nutraceutical and veterinary markets. Bespoke Extracts is headquartered in Sunny Isles Beach, Florida. The Company’s shares trade on the OTC Markets Group’s OTCQB.

The Company’s products are marketed as dietary supplements and distributed through the Company’s direct-to-consumers e-commerce store. Bespoke’s products are produced using pure, all natural, zero-THC phytocannabinoid-rich (PCR) hemp-derived CBD. CBD is non-psychoactive. CBD (cannabidiol) is one of over 85 cannabinoids found in cannabis. CBD is present in more significant quantities in hemp than it is marijuana.

Bespoke Extracts’ mission is to become one of the world’s most trusted sources for premium quality, all-natural, USA-grown, hemp-derived cannabidiol (CBD) products for the nutraceutical and veterinary markets. The Company strives to use only vegan, Fair Trade Certified, and organic ingredients with fast acting benefits for anyone looking for an alternative remedy. Bespoke’s farmers have been innovators in hemp agriculture, farming practices, agrotech, as well as production for generations. Bespoke’s hemp is stable, high in CBD, low in THC, and resistant to pathogens and pests.

The Company’s products include Sport Lemon Lime Tincture – THC Free 1500MG; CBD Manuka Honey Tincture; and CBD Bacon Flavored Pet Tincture. Moreover, products include CBD Softgel Capsules; CBD Pain Relief Cream; and CBD Isolate Powder.

Bespoke Extracts announced this past November that its Board of Directors appointed Niquana (Nikki) Noel as President and Chief Executive Officer (CEO), effective immediately. Serving Bespoke as its Operations Manager, Noel assumed day-to-day leadership of the Company and joined its Board of Directors. Noel has spent close to two decades working with privately-held and publicly-traded micro and small cap companies.

Bespoke Extracts, Inc. (BSPK), closed Friday's trading session at $0.0119, up 40.00%, on 78,165 volume with 10 trades. The average volume for the last 3 months is 41,367 and the stock's 52-week low/high is $0.006/$0.109999999.

chart

Regen BioPharma, Inc. (RGBP)

Small Cap Solutions, InvestorTrendz, Insider Financial, TopPennyStockMovers, YCharts, ProTrader, Emerging Growth, SmallCapVoice, Wall Street Mover, TheMicrocapNews, and The OTC Reporter reported earlier on Regen BioPharma, Inc. (RGBP), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Regen BioPharma, Inc. is a biotechnology company listed on the OTC Markets’ OTCQB. The Company works to identify undervalued regenerative medicine applications in the immunotherapy and stem cell space. Its aim is to quickly advance these technologies through pre-clinical and Phase I/II clinical trials.  Checkpoint Immunology, Inc. is a wholly-owned subsidiary of the Company. Regen BioPharma has its head office in La Mesa, California.

At present, Regen BioPharma is focusing on checkpoint inhibitor and gene silencing therapies for treating cancer. Furthermore, it is focusing  on developing stem cell treatments for aplastic anemia. Fundamentally, the Company is working to increase the quality of life through therapies involving small molecules, stem cell treatments, and the body's own immune system.  It is currently developing products treating blood disorders employing small molecules and gene silencing (DiffronC) and treating cancer with immunotherapy (dCellVax). 

  Regen BioPharma is also modulating vital molecular processes in cancer stem cells by way of its patented molecular targeting approaches (BORIS). In addition, it is repairing damaged bone marrow in patients with aplastic anemia and chemotherapy/radiotherapy treated cancer patients (HemaXellerate). 

  Regen BioPharma is centering on small molecules to activate and inhibit its main target of interest, NR2F6. The Company is continuing to develop the NR2F6 program in-house before entering into any potential partnerships. It has granted CheckPoint Immunology an exclusive international license to develop and commercialize Regen's NR2F6 technology for human therapeutic use. The objective of the license grant is the separation of Regen BioPharma’s small molecule technology from its other Intellectual Property (IP) to facilitate any future transactions involving small molecule therapies focused on the NR2F6 checkpoint.

In September, Regen BioPharma reported that its researchers identified a series of small molecule drugs, which inhibit NR2F6 as well as activate human immune cells ex-vivo. Evidence provided by studies suggest that NR2F6 represses the body's immune response against tumors. Therefore, inhibiting NR2F6 may lead to enhanced immune response against cancerous tumor cells.

Harry Lander, Ph.D., MBA, President and Chief Scientific Officer of Regen BioPharma, said, "Based on the known activities of NR2F6, we expect that inhibiting its activity will lead to increased T cell activation. We found that several of our NR2F6 antagonists can activate human immune cells, such as T cells, leading to increased IL-17a production in a concentration-dependent manner."

Earlier this month, Regen BioPharma reported that its researchers determined that its lead NR2F6 small molecule agonist, RG-NAH005, is now ready for testing in animal models of inflammatory bowel disease (IBD). Regen will pursue this testing as a joint venture (JV) with Zander Therapeutics, Inc. Zander Therapeutics has been granted an exclusive license by Regen to develop and commercialize the Company's NR2F6 IP for veterinary applications.

Regen BioPharma, Inc. (RGBP), closed Friday's trading session at $0.0002, up 100.00%, on 41,015,999 volume with 5 trades. The average volume for the last 3 months is 39,089,029 and the stock's 52-week low/high is $0.00009/$0.0048.

chart

Green Cures & Botanical Distribution, Inc. (GRCU)

Penny Stock Tweets, InvestorsHub, OTC Markets, Business Insider, ClayTrader, Stockopedia, Barchart, GuruFocus, StockGoodies, Capital Cube, Zacks, Front Page Stocks, Simply Wall St, MarketWatch, Stockhouse, Marketwired, Investors Hangout, and Daily Marijuana Observer reported on Green Cures & Botanical Distribution, Inc. (GRCU), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Green Cures & Botanical Distribution, Inc. (GRCU) is a hemp-infused nutrition, botanical, sports, and body care products business. The Company operates a diverse portfolio of products and services within the botanical and cannabis industry, as permitted by law. GRCU is continually creating and introducing products that promote a healthy life style. Listed on the OTC Markets, the Company is based in California.

GRCU announced this past April the expansion of its corporate offices into a new space located in Woodland Hills, California. Also, the Company has received approval from California for GRCU's newest manufacturing plant. The plant had been approved for recreational manufactory and sales in the State of California.

GRCU is currently Web-based. The Company’s focus is on online retailing. Its products are branded under the Original Hollywood Hemp™ brand. Furthermore, it develops beverages branded under the Iconic Beverages ™ name.

Original Hollywood Hemp™ is hemp activated health, beauty, skin care, hair care, spices, fashion, food products and beverages with the active ingredients of hemp. Iconic Beverages™ consists of hemp infused and no hemp infused beverages. Iconic Beverages™ will feature iconic celebrities with exclusive licenses owned by GRCU and its shareholders.

GRCU announced in February 2018 that it signed a four-year agreement with Humboldt Cannabis AF in California to produce licensed cannabis and CBD products. Humboldt Cannabis AF is a cannabis and CBD company in Humboldt, California.

GRCU will look to products to be sold at retail/dispensary. Nevertheless, the Company will rely on Humboldt Cannabis AF for CBD product development. Humboldt has a track record producing top of the line, exclusively pristine product.

In addition, vibrant packaging design for the new GRCU product lines has been finalized. GRCU products are being packaged in their new, striking, provocative, Must Have Packages.

Moreover, GRCU provides online community portals. These sites supply the public with information and resources concerning the benefits of cannabis-derived products.

Green Cures & Botanical Distribution, Inc. (GRCU), closed Friday's trading session at $0.0022, up 37.50%, on 5,690,379 volume with 44 trades. The average volume for the last 3 months is 2,233,781 and the stock's 52-week low/high is $0.000799999/$0.009999999.

chart

Vilacto Bio,  Inc. (VIBI)

OTC Markets and The Street reported on Vilacto Bio,  Inc. (VIBI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Vilacto Bio,  Inc.  is a biotechnology company listed on the OTCQB. It has developed the now fully patented Lactoactive® (Lactoactive molecule). In numerous studies, Lactoactive® has demonstrated above average effect treating conditions such as inflammatory diseases, diabetes, psoriasis, skin aging, and skin issues in different levels. At present the Company’s products are available on the market as Vilact®.

Founded in 2013, Vilacto Bio is headquartered in New York, New York. The Company previously went by the name Zlato, Inc. It changed its name to Vilacto Bio, Inc. on April 4, 2017. The Company’s European Headquarters are in Næstved, Denmark. Its Research and Development (R&D) operations are in Lithuania.

Vilacto Bio’s goal is to be the leading biotechnology company centered on commercializing unique pharmaceutical cosmeceutical products formulated or reformulated with Lactoactive® as nanoparticle according to its patented properties.  The Company’s aim is to further develop its Lactoactive® molecule for increasing the quality of its retail and medical skin cream products, as well as licensing out its Lactoactive® molecule for the pharmaceutical industry.

Lactoactive® is highly refined colostrum, developed to provide first-rate results for people needing healing or relief from a range of skin issues. Lactoactive® is a refined processing of colostrum combined with hyaluronic acid. Proteins in Vilact® survive longer without being degraded by enzymes. This enables them to work longer in the skin. 

Vilacto Bio has its Vilact Cuticle cream product, developed in cooperation with Danish podiatrists. Lactoactive, the ingredient molecule in Vilact Cuticle cream, works to help with skin challenges. Danish podiatrists have demonstrated its use with faster patient recovery.

This past January, Vilacto Bio announced that it started development of the Vilacto Bio Skincare Knowledge Center. This is an online resource that will gather skincare knowledge, science, insights and tips from scientists, dermatologists, podiatrists and other specialists around the world.

The tips and guides presented in the Vilacto Bio Knowledge Center will be shared with industry magazines internationally, and also with Vilacto customers. The expectation is that the Vilacto Bio Knowledge Center will enhance dialogue among specialists and consumers, improve outcomes, and drive higher traffic to Vilacto Bio’s commercial web portal.

Vilacto Bio,  Inc. (VIBI), closed Friday's trading session at $0.0001, up 100.00%, on 2761,300 volume with 1 trade. The average volume for the last 3 months is 10,021,989 and the stock's 52-week low/high is $0.000000999/$0.020999999.

chart

Boston Therapeutics, Inc. (BTHE)

MissionIR,  Tiny Gems, SmallCapVoice, PennyStocks24,   FeedBlitz, Wall Street Mover,  RedChip, TaglichBrothers,  Stock News Now, TopPennyStockMovers, and Information Solutions Group  reported  earlier  on Boston Therapeutics, Inc. (BTHE), and  today we are reporting on  the Company, here at the QualityStocks Daily Newsletter. 

Boston Therapeutics, Inc. is a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. The Company’s product pipeline  centers  on developing and commercializing therapeutic molecules  that  address diabetes and inflammatory diseases. OTCQB-listed,  Boston Therapeutics is based in Lawrence, Massachusetts.

The Company’s  product pipeline includes BTI-320. This is a  non-systemic, non-toxic,  chewable complex carbohydrate-based compound. The design of it is to lessen post-meal glucose elevation. BTI-320 is a proprietary polysaccharide. 

BTI-320 works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes, which break down complex carbohydrates into simple sugars, reducing  the availability of glucose for absorption into the bloodstream. 

Boston Therapeutics  entered a  clinical trial agreement with Joslin Diabetes Center to be the lead clinic  in a Phase II study of BTI-320. In addition,  the Company’s  product pipeline  includes IPOXYN™. This is an injectable anti-necrosis drug. The design of it at first is to treat lower limb ischemia associated with diabetes.  

Boston Therapeutics’  product pipeline also  includes OXYFEX™. This product can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. OXYFEX™ is  the Company’s  veterinary facsimile to IPOXYN™.

Furthermore, Boston Therapeutics  developed and markets SUGARDOWN®. This is a non-systemic,  complex carbohydrate-based dietary food supplement. The design of SUGARDOWN® is to support healthy blood glucose.

SUGARDOWN®, in its present formulation, is a natural sugar blocker dietary supplement product made completely from a non-digestible sugar molecule, which can help people maintain healthier weight levels. It is the first chewable tablet of its kind. 

In 2015, Boston Therapeutics announced that its affiliate, Advance Pharmaceutical Company Limited (APC), began the  SUGARDOWN®  clinical trial in Hong Kong. Advance is evaluating the effect of  SUGARDOWN®  on Post-Prandial Hyperglycemia in Chinese subjects with Pre-Diabetes.  The lead clinical site is the Department of Medicine, The Chinese University of Hong Kong  (CUHK), Prince of Wales Hospital. 

In April 2017, Boston Therapeutics and  Advance Pharmaceutical announced the fully funded new trial plans to support the safety and efficacy of BTI-320, starting with a randomized, placebo-controlled, double-blinded, multi-center, global study on type 2 diabetic (T2D) patients.

Recently, Boston Therapeutics announced that effective sugar reduction with the investigative BTI-320 formulation necessitates only one tablet. Findings were confirmed by the most recent proof-of-concept study conducted in high-risk Chinese subjects with pre-diabetes. A formulation, in the form of a dietary supplement, is currently available as SUGARDOWN®, SUGARBLOCK and SUGARBALANCE in the Unites States and Asia.

Moreover, in December, Boston Therapeutics announced that it expanded its partnership with Advance Pharmaceutical Company Limited (APC) to distribute in Korea. Following the extension of the licensing and distribution agreement with APC, a registered formulation, marketed as a food supplement under the name SUGARBALANCE is now available in Korea. This significant shipment marks a start to the sales of SUGARBALANCE in the territory.

Boston Therapeutics, Inc. (BTHE), closed Friday's trading session at $0.026, up 52.9412%, on 100 volume with 1 trade. The average volume for the last 3 months is 76,459 and the stock's 52-week low/high is $0.0052/$0.05.

chart

The QualityStocks Company Corner

Predictive Oncology (NASDAQ: POAI)

The QualityStocks Daily Newsletter would like to spotlight Predictive Oncology (POAI).

Predictive Oncology Inc. (NASDAQ: POAI), a leader in the cancer precision-medicine field, announced that Pam Prior, CPA, has been appointed to the company's Board of Directors. In addition to holding a seat on the board, Prior will also chair the company’s audit committee. Also today, InvestorBrandNetwork released a report on the company detailing how data and artificial-intelligence- (“AI”) driven, discovery-services company POAI, today announced that it has signed a letter of intent (“LOI”) to acquire Quantitative Medicine (“QM”), a biomedical analytics and computational biology company. By combining QM’s CoRE predictive modeling platform with POAI’s tumor profiling proficiency and data, company management believes the acquisition will assist in fast-tracking the commercialization of its AI-driven technology and services.

Predictive Oncology (POAI) is a knowledge-driven precision medicine company focused on applying data and artificial intelligence (AI) to personalized medicine and drug discovery. The company applies its smart tumor profiling and AI platform to extensive genomic and biomarker patient data sets to build predictive models of tumor drug response to improve clinical outcomes for the cancer patients of today and tomorrow. The company has several tools that support its mission of bringing precision medicine to the treatment of cancer.

Through its subsidiaries, Predictive Oncology’s portfolio of assets includes the following:

  • A database of clinically validated historical and outcome data from patient tumors
  • An in-house Clinical Laboratory Improvement Amendments (CLIA)-certified lab
  • A “smart” patient-derived tumor profiling platform
  • An in-house bioinformatics artificial intelligence (AI) platform
  • A new computerized approach growing tumors in the lab to rapidly develop patient specific treatment options
  • An FDA-approved fluid collection and disposal system

Using these resources, and in collaboration with key players in the pharmaceutical, diagnostic and biotech industries Predictive Oncology is working to determine the best pathways for more individualized and effective cancer treatment.

Subsidiaries

Predictive Oncology leverages the synergies of its three wholly owned subsidiaries to bring precision medicine to the diagnosis of cancer.

Helomics applies artificial intelligence to its rich data gathered from the company’s trove of more than 150,000 tumors to personalize cancer therapies for patients as well as drive the development of new targeted therapies in collaborations with pharmaceutical companies. This database, the largest of its kind in the world, is comprised of ovarian, head and neck, colon and pancreas tumors. Helomic’s CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy.

In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor™ patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary platform (D-CHIP) to provide a tailored solution to its clients’ specific needs.

TumorGenesis is developing a new, rapid approach to growing tumors in the laboratory without the use of rats or mice, allowing for the identification of biomarkers indicative of cancer. This methodology “fools” the tumor into thinking it is still in the body. As a result, the tumor reacts as it naturally would, thereby increasing the accuracy of the biomarker. Once the biomarkers are identified, they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and helps categorize an individual patient’s heterogeneous tumor samples to enable development of patient-specific treatment options.

Skyline Medical’s patented, FDA-cleared STREAMWAY® System is the first true, direct-to-drain fluid disposal system designed specifically for medical applications such as radiology, endoscopy, urology and cystoscopy procedures. The STREAMWAY system is changing the way healthcare facilities collect and dispose of potentially infectious waste fluid by connecting directly to a facility’s plumbing system to automate the collection, measurement and disposal of waste fluids.

The STREAMWAY minimizes human intervention for better safety and improves compliance with Occupational Safety and Health Administration (OSHA) and other regulatory agency safety guidelines. The STREAMWAY eliminates canisters, carts and evacuated bottles, which reduces overhead costs and minimizes environmental impact by helping to eliminate the approximately 50 million potentially disease-infected canisters that go into landfills annually in the United Sates.

Skyline has achieved sales in five of the seven continents through both direct sales and distributor partners.

Competitive Advantage

Precision medicine has become the holy grail of cancer therapeutics. Data driven predictive models of tumors and their responses are critical in both new drug development and individualized patient treatment. The race has begun to model various tumors, which takes 5 to 7 years of clinical evaluation to establish historical and outcome data.

Predictive Oncology enjoys significant competitive advantage. The company already has a vast historical collection of tumors and related data, plus the ability to obtain existing associated outcome data. While others wait for outcome data, Predictive Oncology is in a unique and powerful position, working to deliver the promise of precision medicine to reality. Predictive Oncology already has the clinical data, including how a tumor responded to certain drugs, an in-house bioinformatics AI platform, and only needs to do the tumor sequencing. The significance is underscored by the collaboration with UPMC Magee-Women’s Hospital, designed to reveal which mutations responded to which drug then develop powerful predictive models for future testing and treatment.

Leadership Team

Dr. Carl Schwartz was appointed to Skyline Medical’s board of directors in March 2015 and became interim president and CEO in May 2016. Dr. Schwartz became CEO of Plastics Research Corporation in 1988, leading the company to become the largest manufacturer of structural foam molding products in the U.S. with more than $60 million in revenues and 300 employees by the time he retired in 2001. He holds a bachelor’s degree and DDS degree from the University of Detroit.

CFO Bob Myers has over 30 years of experience in multiple industries focusing on medical device service and manufacturing. He has spent much of his career as a CFO and controller. Myers holds an MBA in Finance from Adelphi University and a BBA in public accounting from Hofstra University.

Gerald Vardzel, President of Helomics, has over 25 years of healthcare executive management experience developing and implementing commercialization strategies and models for technology launches. His Go-To-Market expertise includes equity financing, strategic planning, market intelligence, M&A, and new market development in both start-up and established settings including fortune 500 market leaders. He has developed innovative solutions for both CLIA and FDA regulatory paths defining the delivery chains from discovery to clinical acceptance. Mr. Vardzel also has significant experience designing and implementing sales and marketing programs tailored not only to expand market share, but to empirically assess client satisfaction, strengthen business processes, and maximize profitability. Mr. Vardzel was previously Vice President of Corporate Development and Strategic Initiatives at Global Specimen Solutions. Furthermore, as an executive affiliate to the healthcare industry, he routinely consults for several small-to-mid sized private equity firms advising on, in part, the feasibility of acquisition targets. Mr. Vardzel graduated from the University of Pittsburgh.

Dr. Mark Collins, Chief Information Officer of Helomics, has held multiple executive roles in a variety of discovery, informatics and bioinformatics functions within global pharma, and founded three startup software companies in the machine learning and drug discovery space. In 2001, Dr. Collins worked for Cellomics (now part of Thermo Fisher Scientific), where he played a pivotal role in establishing the High-Content Cell Analysis market, building and commercializing several key informatics and bioinformatics products. After leaving Thermo Fisher, Dr. Collins developed and commercialized informatics solutions for clinical and translational research, specifically in the specimen tracking, omics data management and NGS analysis space, through key roles at BioFortis, Global Specimens Solutions and Genedata. Dr. Collins received his undergraduate degree in Applied Science from the University of Wolverhampton, UK and his Ph.D. in Microbiology from the University of Surrey, UK.

Predictive Oncology (POAI), closed Friday's trading session at $2.84, up 4.4118%, on 270,998 volume with 1,124 trades. The average volume for the last 3 months is 39,575 and the stock's 52-week low/high is $2.28999996/$8.50.

Recent News

chart

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences and other industries, today announced its receipt of a purchase order from a new customer for six proprietary Ultra Shear Technology(TM) (“UST”)-based nanoemulsification systems for processing CBD oil into stable, effectively water-soluble, highly absorbable nanoemulsions of oil in water. To view the full press release, visit http://cnw.fm/OhB2y. Also today, the company was highlighted in a publication from Financialnewsmedia.com, examining how recent industry reports show that the recreational cannabis beverage industry is on the rise, and nanoemulsion-infused beverages are leading to the development of drinkable cannabis products that are both potent and fast acting. Transparency Market Research (TMR) is predicting an increased growth in the global nanoemulsion market. Valued at US$6.78 Billion in 2016, it’s estimated to rise to $14.91 billion by the end of 2025.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Friday's trading session at $2.40, up 80.4511%, on 127,343 volume with 366 trades. The average volume for the last 3 months is 15,538 and the stock's 52-week low/high is $0.600600004/$4.0300002.

Recent News

chart

Sigma Labs Inc. (NASDAQ: SGLB)

The QualityStocks Daily Newsletter would like to spotlight Sigma Labs Inc. (SGLB).

City expansion fueled by global population growth is creating ever increasing demand for sustainable compact electric vehicles as a means of traversing increasingly complex urban environments. The 3D metal-printing industry is helping to bring these concept vehicles to life through the 3D formation of many requisite parts – from interior consoles, display frames, plug socket fixtures, air vents and lidar screens right down to license plates (http://nnw.fm/PcT5e). Quality control remains one of the prime impediments to the entire auto industry to reach scalability and profitability using 3D printing. Sigma Labs Inc. (NASDAQ: SGLB), with its revolutionary software, is the only provider of in-process, quality-assurance software to the global 3D metal-printing industry.

Sigma Labs Inc. (SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

Sigma Labs Inc. (SGLB), closed Friday's trading session at $0.94, up 1.2931%, on 28,953 volume with 96 trades. The average volume for the last 3 months is 196,048 and the stock's 52-week low/high is $0.451099991/$2.45000004.

Recent News

chart

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF)

The QualityStocks Daily Newsletter would like to spotlight Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF).

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) was featured today in the 420 with CNW by CannabisNewsWire. Canadian mothers who are also marijuana consumers have been complaining that they are criticized more than dads who are weed consumers. In the past few months, several organizations have been established to provide mothers with a safe place to discuss marijuana and reduce stigma surrounding moms who use marijuana.

Willow Biosciences Inc. (TSX: WLLW) (OTCQB: CANSF) is a leading developer of biosynthetic production systems for high-value, plant-derived active pharmaceutical ingredients (“APIs”) and intermediates. The company’s cannabidiol (“CBD”) yeast-based biosynthesis program produces a high yield, ultrapure, low-cost and scalable manufacturing solution for pharmaceutical, food, beverage and personal care consumers of CBD.

The company is headquartered in Calgary, Alberta, Canada.

Biosynthesis Platform

Willow’s proprietary yeast-based lab strains produce CBD, tetrahydrocannabinol (“THC”), and cannabigerol (“CBG”), as well as certain minor and novel cannabinoids.

The company’s expertise in the esoteric field of biosynthesis and in delivering commercial fermentation pathways for the production of pharmaceutical-grade compounds grew from its origins in opiate research. Willow recently delivered a de novo biosynthesis pathway in yeast for thebaine, a key precursor API used as a feedstock in the manufacture of semi-synthetic opiates such as naloxone (used to reverse opioid overdose) and several common analgesics. Led by Chief Scientific Officer Dr. Peter Facchini, Willow’s research team discovered and patented numerous previously unknown genes coding for core catalytic pathway enzymes, as well as a number of additional non-pathway, yet commercially-essential, accessory genes.

Utilizing this proven synthetic biology platform, Willow’s research team has already begun producing cannabinoids at lab scale, using yeast as the host cell “factory.” This biosynthetic fermentation-based process is capable of producing pharmaceutical grade CBD in 10 days – far less time than traditional plant-based extraction methods.

Willow anticipates its technology can be scaled to produce hundreds of kilograms per batch of cannabinoid API at less than $1,000 per kilogram, thus costing approximately 60% less than current chemical synthesis methods and 90% less than conventional plant-based extraction methods.

World-Class Collaboration

Willow and Noramco Inc., the world’s largest producer of high-quality synthetic cannabinoid APIs and other controlled substance APIs for the pharmaceutical and healthcare industry, have an exclusive, worldwide Joint Development Agreement (“JDA”) to design a yeast-based biosynthesis platform for the production and distribution of a highly pure CBD isolate.

The mutually exclusive agreement calls for Willow to be responsible for optimizing yeast strains in a biosynthetic process to generate ultrapure CBD at high yield and substantially lower cost compared to current methods. Noramco will leverage its decades of experience in producing and delivering CBD and pharmaceutical APIs by being responsible for the scale-up, regulatory submission, marketing and distribution of products manufactured under the JDA.

Each company will invest comparable funds, will retain the intellectual property associated with their respective scopes of work and share equally in gross profits from sales of products manufactured under the JDA.

Market Opportunity

The agreement with Noramco (http://nnw.fm/Mz1vW) addresses the increasing demand for CBD-based APIs and other CBD-infused products by pharmaceutical, nutraceutical, consumer packaged goods, beverages and other industry sectors.

The U.S. market potential of cannabinoids is significant, with industry analysts projecting $50 billion in cannabinoid-based pharmaceutical sales and $16 billion in CBD consumer goods retail sales by 2025. As of June 2019, 34 U.S. states and the District of Columbia, Guam, Puerto Rico and U.S. Virgin Islands have legalized cannabis for medical use. Another 13 states and territories have approved recreational cannabis for adult use while other states are considering similar measures.

The cannabinoid API market continues to evolve with CBD and other cannabinoid-based treatment options currently in clinical trials for indications such as post-traumatic stress syndrome, epilepsy, Parkinson’s disease, chronic pain, schizophrenia, cancer treatments and other challenging unmet medical conditions.

Capitalization

Willow is fully funded after raising $29 million via private placement and $8 million in exercised warrants by Tuatara Capital Fund II, L.P. Proceeds of the funding will be used to enhance the existing laboratory space in Calgary and Vancouver, Canada, and in San Francisco, California. The company anticipates exiting 2020 with $15.8 million in cash.

Leadership

President and CEO Trevor Peters is an experienced executive who co-founded four startup companies in the past 15 years. He has raised over $1 billion in equity and debt financings at various stages of corporate development and has been integral to successful transactions totaling over $4 billion on sale. Mr. Peters previously was chief financial officer at Caracal Energy Inc., which sold to Glencore plc in 2014 for $1.8 billion.

Chief Financial Officer Travis Doupe has over 18 years of experience in financial leadership roles, principally in the international oil and gas industry, where he provided corporate strategic direction while overseeing all aspects of financial operations. Mr. Doupe is the treasurer and a member of the board of directors of the Canada Council for the Americas – Alberta and holds a CA-CPA designation and earned a bachelor’s degree in management from the University of Calgary.

Dr. Peter Facchini, Chief Scientific Officer, has been professor of plant biochemistry in the Department of Biological Sciences at the University of Calgary since 1995. He is recognized internationally as a leader in plant specialized metabolite biosynthesis. Dr. Facchini is the Canada Research Chair in Plant Metabolic Processes Biotechnology and has published more than 150 research papers and scholarly articles. Dr. Facchini received a PhD from the University of Toronto and conducted postdoctoral research at the University of Kentucky and Université de Montréal.

Dr. Joseph Tucker, Executive Chairman of the Board of Directors, holds more than 20 issued or pending patents and is a member of the Board of Directors of BioAlberta. He has extensive senior leadership experience in multiple public and private biotech companies. Dr. Tucker received a PhD in biochemistry and molecular biology from the University of Calgary.

Willow Biosciences Inc. (OTCQB: CANSF), closed Friday's trading session at $0.61, up 0.494234%, on 1,000 volume with 1 trade. The average volume for the last 3 months is 10,262 and the stock's 52-week low/high is $0.400999993/$2.1775.

Recent News

chart

ChineseInvestors.com (CIIX)

The QualityStocks Daily Newsletter would like to spotlight ChineseInvestors.com (CIIX).

ChineseInvestors.com (OTCQB: CIIX) was featured on this week’s episode of MoneyTV with Donald Baillargeon. The internationally syndicated program, viewed in over 200 million households and more than 75 countries, covers money-focused topics and features in-depth interviews with CEOs and executives that offer insights into various companies and their operations and future outlooks. To view the full press release, visit http://cnw.fm/4zL2g. Also today, the company was highlighted in a publication from CBDWire. After realizing the multitude of opportunities in the growing cannabis sector, especially concerning China’s nascent CBD market, CIIX has worked to cultivate an attractive lineup of products through its subsidiary CBD Biotech. While cannabis is still highly illegal in China, hemp-based CBD can be legally added to cosmetics. The team at CIIX recognizes the massive potential of the untapped Chinese CBD market.

Founded in 1999, ChineseInvestors.com (CIIX) has become a leading financial information website for Chinese-speaking investors in the United States and China. Recognizing unprecedented opportunities in the U.S. cannabis industry, CIIX is also laying the groundwork to capitalize on growing demand for cannabidiol (CBD)-based nutrition and health products.

Through its primary website, www.ChineseInvestors.com, CIIX offers a variety of investor education products and services, including real-time market commentary, analysis and educational related services in Chinese language character sets; consultative services to smaller private companies considering becoming a public company; and advertising and public relations related support services.

At the center of this initiative is the ChineseInvestors Method, a unique integration of a disciplined investing process, web-based tools, personalized instructions and support. Using this strategy, CIIX provides reliable market information to help investors make informed investment decisions and meet their individualized financial goals.

CIIX is also leveraging its financial expertise to enter into the burgeoning CBD industry, which within a few years has grown from a relatively invisible sector to a billowing market expected to reach $2.1 billion in consumer sales by 2020.

The increasing demand for CBD-based products is a catalyst for innovative business endeavors. To this accord, CIIX has established a three-year development plan to capitalize on the convergence of CBD and the nutrition and health products market in mainland China, where the benefits of CBD oil have not been widely recognized.

Under a wholesale agreement with a reputable CBD health brand, CIIX is launching the world’s first online CBD health products store published in the Chinese language. The site, www.ChineseCBDoil.com, caters to a growing number of Chinese people awakening to the numerous health benefits of CBD oil for treatment of a variety of conditions such as anxiety, stress, poor sleep, Alzheimer’s disease, and more. CIIX expects to launch this website at the end of January 2017, and plans to sell CBD-infused products via online and in-store.

In conjunction, CIIX’s cannabis-focused “Yelp”-style mobile app is in development as a platform for Chinese people to review and discuss various cannabis products. The app will be the first marijuana social media mobile app designed for Chinese-speaking customers worldwide.

ChineseInvestors.com (CIIX), closed Friday's trading session at $0.19, up 8.5714%, on 36,865 volume with 9 trades. The average volume for the last 3 months is 51,411 and the stock's 52-week low/high is $0.150000005/$0.550000011.

Recent News

chart

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF)

The QualityStocks Daily Newsletter would like to spotlight HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF).

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF), a hemp-biomass processing entity, is leveraging its patented Delta Purification(TM) technology that reduces cannabidiol (“CBD”) waste during the extraction process to position itself for success in the booming market. To view the full article, visit http://cnw.fm/X0hc3

HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) has developed and optimized proprietary technologies designed for biomass extraction, distillation and purification of ethanol and ethanol-based solvents used for the hemp biomass and cannabidiol (“CBD”) industry, as well as gas and liquid extraction. HTC’s extraction & purification systems are engineered to large-scale to reduce capital and operating costs while delivering superior performance measured by reduced energy usage, lowered emissions and improved quality of the product produced.

Advanced Extraction Technologies

For more than 14 years, HTC has developed and optimized proprietary technology and purification systems used for biomass, gas and liquid extraction. These technologies include:

  • LCDesign® – Low-cost design for modular gas, liquid and biomass extraction systems optimizes plant design, thus reducing capital and operating costs.
  • PDOEngine™ – Software-based design algorithms accurately model and simulate gas, liquid and biomass extraction processing.
  • Delta Solvents™ – Custom-designed, ethanol-based solvent mixtures and additives that optimize production and reduce costs. Technology development is being conducted at HTC’s sponsored research facilities at the University of Calgary.

Delta Purification® Technology

HTC’s patented Delta Purification® technology will purify, recycle and reuse the extraction ethanol used in the CBD extraction process while managing and reducing any CBD waste losses through the re-extraction of all wastes collected from the purified ethanol. Current and new technologies include:

  • Delta CBD Reclaiming System: Reclaiming and purifying ethanol for use in CBD extraction from biomass. Reduces required heat to prevent damage of the chemical attributes of the CBD molecule, allowing extracted CBD to meet food-grade targets for human consumption.
  • Delta Solvent Reclaiming System: Reclaiming and purifying ethanol-based solvents, such as single, mixed and formulated amines, for use in natural gas processing and post-combustion CO2 capturing processes.
  • Delta Glycol Reclaiming System: Reclaiming and purifying glycols, such as mono-ethylene glycol and tri-ethylene glycol for use in natural gas dehydration processes.

Hemp Biomass and Tolling Contracts

HTC has entered into a hemp biomass tolling agreement for the 2019 crop year involving a supply of hemp biomass from a hemp grower in Saskatchewan, Canada. The hemp grower utilizes five varieties of Health Canada-approved cultivars as the genetic foundation. HTC will process and extract CBD FSO distillate from the hemp biomass. As a tolling fee payment, HTC will receive a percentage of the extracted CBD FSO distillate for its processing, extraction, purification and distillation services.

Additional hemp biomass tolling contracts with producers and hemp biomass providers are being negotiated in the U.S. for the 2020 hemp crop growing year. HTC will provide “local-to-grower” drying-to-biomass storage capability and transportation of dried biomass to an HTC, location to be determined, future US based, extraction facility. HTC is also in negotiation with a 60,000-acre, recognized Canadian farm leader, who is a significant hemp biomass producer, for a similar hemp biomass tolling contract.

re3™ Technology

Large users of ethanol and solvents for plant oil extraction demand reduced capital and operating costs. HTC’s re3™ (reclaim, recycle, reuse) technology can save up to 30% of the required fluid costs. The increasing cost of new extraction ethanol, combined with the cost of used ethanol disposal, creates a unique opportunity whereby the re3™ technology will create cost savings, while meeting environmental responsibilities.

The growth of ethanol and CO2 used in CBD production has created a new demand for reliable commercial scale ethanol reclaimer systems. The Delta Purification® ethanol system meets this new demand.

Sales and Offtake Agreements

HTC intends to leverage its relationship with its related entity, Purely Canada Foods™, to provide sales and distribution for its Ingredient CBD market under the brand of Purely Canada Hemp™, Purely Canada CBD™, Purely Canada Cannabinoids™. Purely Canada Hemp™ will develop risk managed multi-year ingredient supply contracts with its existing and new Global Food, Beverage and Animal Food Industry Customers.

Project Construction

HTC has focused the Canadian implementation of its BOOM (build, own, operate and maintain) extraction tolling strategy on a location near Regina, Saskatchewan. HTC is currently constructing a 19,000-square-foot GMP Euro compliant extraction tolling facility on six acres of land that will include biomass processing, extraction, implementation of DeltaSolv™ technologies and Delta Purification® systems, distillate and refining equipment, laboratory quality control and testing operations, and on-site office and admin facilities.

Leadership

Chairman, CEO and Director Lionel Kambeitz is a recognized professional in business development and international business relations. He has played a founding role in many other Canadian and U.S.-based companies. Kambeitz has executive experience in a variety of industries including energy, agriculture, food production engineering, and manufacturing.

Jeff Allison, Senior Vice President, Chief Financial Officer and Director, has over 20 years of experience in corporate finance and business development. Prior to joining HTC in 2005, Allison as Vice President assisted with the founding and setup of CUCORP Financial Services in Saskatchewan.

HTC Extraction Systems (OTCQB: HTPRF), closed Friday's trading session at $0.1852, even for the day, on 150 volume. The average volume for the last 3 months is 2,841 and the stock's 52-week low/high is $0.100299999/$0.920000016.

Recent News

chart

InsuraGuest Inc.

The QualityStocks Daily Newsletter would like to spotlight InsuraGuest Inc..

InsuraGuestis a SaaS (Software-as-a-Service) company that, through its proprietary flagship InsurTech software platform, provides specialized insurance products. An article discussing the company reads, “Service-as-a-software (SaaS) company InsuraGuest Inc.’s Guest Protection Policy, sold to hotels and vacation rental properties through its proprietary InsurTech software platform, and extended to the guest from the time of check-in to check-out. To view the full article, visit http://nnw.fm/jQf3g.

InsuraGuest Inc. is a SaaS (Software-as-a-Service) company utilizing its proprietary flagship InsurTech software platform to provide specialized insurance products to end users in the business-to-business (B2B) and business-to-consumer (B2C) markets. The company’s first focus is on the B2B hotels and vacation rentals sectors, where its API integrates with the clients’ property management systems to offer guests a specialized guest protection policy. The platform and policy combination “InsurTech” product helps transfer the exposure to liability away from the client/property while guests benefit from potential accident and loss coverage during their stay.

InsuraGuest’s platform is currently capable of integrating with approximately 70 different hotel and vacation rental property management systems, giving it access to roughly 40,000 properties worldwide.

The company continues to pursue expansion opportunities and recently signed a Letter of Intent with a master general agent in the United Kingdom and Europe to distribute its platform and products to hotel and vacation rental markets in those regions, as well as plans to expand to Asia in 2020.

Protecting Guests, Enhancing Customer Experience

InsuraGuest is the first line of defense for both the property and the guest.

InsuraGuest is purchased by the hotel or vacation rental “property,” which offers the policy to each registered guest and its occupants for an additional fee. The specialized policy affords coverage for theft of personal property while in the hotel, as well as accidental medical expense and accidental death and dismemberment, up to the policy limits of $2,500 to $50,000.

Market Opportunity

The U.S. hotel industry generated more than $218 billion in annual revenues in 2018, an increase of $10 billion from the previous year, according to STR’s 2019 HOST Almanac. The European market is more than double the size of the U.S. market. According to Oxford Economics, there were 6.4 billion nights stayed in the world, with 2.6 billion hotel nights in Asia, 2.8 billion nights stayed in Europe, and 1.1 billion nights in the United States. Additionally, $100 billion was spent on vacation rentals in the United State alone, where there are approximately 4.5 million second homes are being managed by a third-party rental company.

With distribution in Europe and the United States, InsuraGuest’s demographics combined will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

Within this burgeoning, high-demand industry is risk of liability to guest injury. For example, gym injuries are among the top five most common hotel accidents. Without proper hedges in place, the property may be liable in a personal injury claim or lawsuit.

Though the potential for accidents, slip and falls and mishaps can be widespread, it can be covered under the InsuraGuest Specialized Guest Protection Policy to provide guests a worry-free and enjoyable stay that potentially increases loyalty for the property.

Business Highlights

  • Targeting hotels and vacation rentals, a multi-billion-dollar industry
  • Providing the first line of defense in case of accident, loss or death
  • Expanding distribution reach with footing in European hotel and vacation rental markets
  • Expansion into Asia by 2020

Executive Team

Douglas Anderson, Chairman & Chief Executive Officer
Douglas Anderson has been a businessman in the real estate industry for nearly 30 years. His business expertise includes master planning and development implementation for larger-scale resorts, business parks and commercial developments across the USA and two provinces in Canada. His business endeavors include the founding of the 7th larger private equity fund in America focusing on multifamily and senior care (ROC Fund/Bridge IPG Fund). He serves as chairman/founder of a golf and winter sports ski holding company with operations in four major east coast markets and British Columbia, Canada.

Anderson earned a BS undergraduate degree in Consumer Studies with an emphasis in Architecture as an undergraduate at the University of Utah. He subsequently earned his Master’s in Business Administration. He also attended a three-year OPM Program a postgraduate business education at Harvard Business School in Boston. Anderson is an avid skier and outdoor enthusiast.

Charles James Cayias, President & Director
Charles James Cayias is also the president and owner of Charles James Cayias Insurance Inc. He is a third-generation insurance professional whose creativity and artistic vision have enabled him to establish a full-service agency combined with the personal service each client deserves. His outstanding people skills, honesty, integrity and fairness are evident by his loyal and growing clientele, the majority of which are referrals who become long-time customers and friends.

Cayias began his insurance career in the early 1970s and has been licensed since 1977. He is licensed in all 50 states and specializes in niche programs. He has extensive expertise in all aspects of the insurance industry including commercial insurance, employee benefits, workers’ compensation, professional liability, risk management and bonding.

Christopher J. Panos Vice President & Director
Christopher J. Panos is a highly competitive sales professional with over 15 years of territory manager sales experience and an award-winning record of achievements. He is exceptionally well organized with a proven work history that demonstrates self-discipline, superb communication skills, and the initiative to achieve both personal and corporate goals. Panos is successful in building relationships with a large network of industry professionals in order to grow and maintain new and existing business, exceed new sales objectives and provide in-depth product training to authorized dealers and sales personnel.

Alexander Walker III ESQ, Corporate Counsel & Director
Alexander Walker III ESQ has served as director of the company since September of 2018. He also has served as counsel to the company since July of 2018. Walker is an attorney and has been a member of the Utah Bar Association since 1987 and a member of the Nevada State Bar since 2003. His practice has involved general business litigation, in both federal and state courts, and transactional work, including securities offerings and registration, corporate formation and periodic reporting compliance. Walker has provided legal services to emerging businesses throughout his carrier and at times has served as an officer and board member as well as legal counsel public companies. His duties as legal counsel for a public company engaged in the business of ownership and operation of coal-producing properties in the western United States included oversight of corporate-related legal matters including securities reporting, corporate compliance, federal and state mining regulation, and employment law oversight. He also has served as the chair of the Mining Committee of the Energy, Natural Resources and Environmental Law Section of the Utah State Bar, a member of the board of directors of the South East Utah Energy Producers Association, the co-chair of the board of the Western Energy Training Center, a board member of the Utah Supreme Court Committee to Review the ABA Recommendations Regarding the Office of Professional Conduct, and a board member of the University of Utah Crimson Club.

Roger Bloss, Corporate Consultant & Board Advisor
Roger Bloss joined InsuraGuest in August of 2019 to advise the company and its board on hotel transactions, contributing his knowledge from more than 40 years in the hospitality industry. Bloss previously served in executive positions with several major hotel franchise companies and in 1996 founded Vantage Hospitality Group hotel brands. Under his leadership, Vantage became a Top 10 global hotel company and made the Inc. 500/5000 list of Americas’ fastest-growing private companies for eight straight years. Bloss was named Lodging Magazine’s “Innovator of the Year” in 2006 and 2010, and in 2009 earned a spot on HSMAI’s “Top 25 Extraordinary Minds in Sales and Marketing.” Bloss joined Red Lion Hotels Corporation (RLHC) in September 2016 in conjunction with the acquisition of Vantage.


Recent News

chart

Xalles Holdings Inc. (OTC: XALL)

The QualityStocks Daily Newsletter would like to spotlight Xalles Holdings Inc. (OTC: XALL).

Xalles Holdings (OTC: XALL), a fintech holding company, recently entered into a partnership with All The Numbers Trading Company LLC (d/b/a ATN Trading) that will enable XALL to offer its customers access to ATN Trading’s fast and efficient crypto-trading engine. To view the full article, visit http://ccw.fm/3ByXR.

Xalles Holdings Inc. (OTC: XALL) is a fintech holding company leveraging blockchain and other technologies for e-commerce, payments, financial reconciliation, and payment auditing solutions. The company actively seeks acquisition targets with strong management teams and business models, large total attainable markets, and lucrative exit opportunities in which to invest and accelerate growth.

Operations

The common element to all acquired entities and projects is a business model that involves setting up a payment or financial transaction “toll gate,” thereby creating a recurring revenue stream.

Xalles’ business plan focuses on consumer, business and government-oriented payment and financial reconciliation transactions. Combining the blockchain decentralized financial ledger platform with the company’s existing X2X transaction reconciliation system design, Xalles is building technology that supports payment audits, exchanges, and new business models and opportunities worldwide. Xalles will launch new services card and mobile payment and rewards systems, and will expand the technology offerings for referral marketing and e-commerce engines.

Subsidiaries
(all current subsidiaries are wholly owned)

  • Xalles Holdings
    Raise capital for fintech accelerator program acquisitions, provide management, administrative, finance and marketing support to all subsidiary companies
  • Xalles Capital
    Management support of investment consortiums, direct investment into funds or projects, and management of investments
  • Xalles Limited
    Design and market new X2X solutions; acquire U.S Government transportation post-payment audit business through GSA schedule and expand to non-transportation payment auditing
  • Xalles Technology
    Technical development of the X2X blockchain systems
  • Xalles Financial Services
    Consumer and small business financial service offerings
  • Co-Owners Rewards
    Stock-based rewards system for payments cards and financial services
  • Amazing Living Enterprises
    Affiliate program and e-commerce platform for enhancing financial lives
  • Global Savings Network
    Not-for-profit fundraising system with consumer discounts at local merchants

X2X Solutions

Xalles provides payment and financial transaction management solutions through the company’s proprietary blockchain-based X2X technology. The X2X solution includes the Investment and Financing System (IFS), which supports complex investment structures, assists international investment consortia, and provides links to Xalles’ Financial Transaction Reconciliation (FTR) solution. FTR supports complex financial ecosystems, making it easier for parties to exchange products, services, grants and government incentives, and assists “Exchange Managers” with liquidity and auditability. X2X also supports the Xalles pre- and post-payment auditing services.

Plans for 2020

  • Xalles expects to announce new acquisitions of fintech growth firms.
  • The company’s strategy for 2020 includes revamping its consumer Commerce platform, to bring in the best elements of local and online shopping with payment tools and a unique rewards program.
  • Xalles Financial Services expects to expand its cryptocurrency related service offerings through partnerships, acquisitions and organic growth
  • The Blockchain based X2X system will continue to be enhanced to deliver new financial reconciliation services to large enterprises and governments.

Xalles Holdings Inc. (OTC: XALL), closed Friday's trading session at $0.0019, even for the day, on 84,750 volume with 3 trades. The average volume for the last 3 months is 1,737,140 and the stock's 52-week low/high is $0.0013/$0.021029999.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Plus Products (CSE: PLUS) (OTCQB: PLPRF), a hemp and cannabis food company using nature to bring balance to consumers’ lives, is executing a strategy to become the world’s strongest cannabis brand by establishing itself as a strong Consumer Packaged Goods (“CPG”) company in California. Following its success in the Golden State, the company plans to move on to new markets, products and consumers (http://cnw.fm/O0fDc). To view the full article, visit http://cnw.fm/wP5TA.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed Friday's trading session at $1.10, off by 0.900901%, on 14,254 volume with 24 trades. The average volume for the last 3 months is 50,641 and the stock's 52-week low/high is $0.839999973/$6.00810003.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) was featured today in a publication from HempWireNews, examining how it has emerged that a number of U.S. states are opting to apply the 2014 hemp pilot program law this despite the USDA publishing interim final rules for hemp. For example, Maine’s state horticulturist, Gary Fish, said that after observing the uncertainty within the USDA rules, they decided that it would be better for their growers if they maintained their pilot program.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary DehydraTECH™ technology for improved taste, rapidity and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECH technology to improve taste, remove odor and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada and the United States. Lexaria has also developed its own hemp-oil brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea and supplements. These brands include ViPova™, TurboCBD™ and ChargD+™.

Virtually unique across both the hemp and the cannabis industries, Lexaria has successfully entered into a R&D and product development partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Only a small handful of hemp or cannabis-related companies have achieved formal relationships with Fortune 500 industry leaders, demonstrating the wide applicability of Lexaria’s technology.

In June 2019, building on its original 2015 independent, third-party laboratory in vitro lab experiments, which confirmed the absorption levels of cannabidiol (“CBD”) into human intestinal cells rose by 499% through the utilization of the DehydraTECH technology, Lexaria completed a series of animal studies using an enhanced formulation of its DehydraTECH technology. The results of the animal studies using the enhanced DehydraTECH formulation showed an increase of CBD delivery into the blood when compared to generic industry MCT coconut-oil formulations by 811%. In addition, the animal studies also showed delivery of 1,937% more CBD into animal brain tissue after 8 hours using the enhanced DehydraTECH technology when compared to generic industry MCT coconut-oil formulations.

Lexaria also has completed the first phases of its collaborative research program with the Canadian government’s National Research Council (the “NRC”) under which several studies were designed to optimize Lexaria’s DehydraTECH technology, enabling delivery of API’s within foods, beverages, capsules and other ingestible formats. These studies investigated the lipophilic active agent classes including cannabinoids, vitamins, NSAIDs and nicotine using advanced analytical techniques, including mass spectrometry and nuclear magnetic resonance testing, with the results of the studies confirming that Lexaria’s DehydraTECH technology did not create any covalent-bonded new molecular entity (“NME”). Whenever an NME is created, regulatory bodies such as FDA and Health Canada routinely require extensive health, safety and efficacy studies prior to that product’s release into the marketplace. That the NRC program failed to find evidence of an NME suggests products utilizing the DehydraTECH technology may require a less burdensome regulatory pathway.

Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: hemp/CBD; pharmaceutical; cannabis; and nicotine. In August 2019, Lexaria was issued its cannabis research and development licence from Health Canada which will allow Lexaria to continue its further investigations in-house of its DehydraTECH technology in connection with cannabinoids, along with ongoing work with vitamins, NSAIDs, PDE5-inhibitors, nicotine and other molecules.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the August 2019, the company’s patent portfolio includes ~60 patent applications filed and pending in more than 40 countries around the world; and 16 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally by the end of 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others. Lexaria’s granted patent portfolio related to cannabinoid delivery is one of the largest in the world.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology to third-partners and has signed licensing agreements with start-up companies as well as with a Fortune 100 industry leader. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Friday's trading session at $0.50, off by 5.6604%, on 77,240 volume with 76 trades. The average volume for the last 3 months is 122,419 and the stock's 52-week low/high is $0.3037/$1.57000005.

Recent News

chart

MCTC Holdings Inc. (OTC: MCTC)

The QualityStocks Daily Newsletter would like to spotlight MCTC Holdings Inc. (MCTC).

MCTC Holdings Inc. (OTC: MCTC) was featured today in a publication from CBDWire, examining how cannabidiol, or CBD, has been making waves recently, especially in the medical, sports, health and wellness communities. Extracted from hemp, the chemical is said to be an extremely potent natural medicine. Some of the conditions users claim CBD works against include chronic pain, high blood pressure, and anxiety. Hemp is part of the cannabis family, with the difference being THC (delta-9 tetrahydrocannabinol) levels, and research into how cannabis interacts with the body led to the discovery of the endocannabinoid system (ECS).

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://nnw.fm/v6RQ6).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://nnw.fm/cK3Bl):

  • Significantly improving bioavailability
  • Allowing for ultra-high loading rates
  • Enhancing customization of cannabinoid combinations
  • Improved dosing precision
  • Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://nnw.fm/57Fjh). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

  • The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
  • Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
  • Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
  • Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. (OTC: MCOA). He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

MCTC Holdings Inc. (MCTC), closed Friday's trading session at $0.44, off by 1.1236%, on 8,836 volume with 15 trades. The average volume for the last 3 months is 15,947 and the stock's 52-week low/high is $0.090000003/$3.00.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

SinglePoint (OTCQB: SING) was featured on this week’s episode of MoneyTV with Donald Baillargeon. The internationally syndicated program covers money-focused topics, featuring various companies and in-depth interviews with CEOs and executives that offer insights into operations and future outlooks. To view the full press release, visit http://cnw.fm/ip3Ku

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Friday's trading session at $0.00875, off by 2.7778%, on 5,152,057 volume with 97 trades. The average volume for the last 3 months is 3,299,927 and the stock's 52-week low/high is $0.007/$0.023499999.

Recent News

chart

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF)

The QualityStocks Daily Newsletter would like to spotlight Canopy Rivers Inc. (RIV) (CNPOF).

Canopy Rivers Inc. (TSX: RIV, OTC: CNPOF), a venture capital firm specializing in cannabis, will report its third quarter fiscal year 2020 financial results before markets open on Friday, February 14, 2020. The Company's unaudited condensed interim consolidated financial statements and management's discussion and analysis of financial results for the nine months ended December 31, 2019 will be available on the Company's profile on the System for Electronic Document Analysis and Retrieval ("SEDAR") at www.sedar.com and on the Company's website at www.canopyrivers.com/investors/financials-and-public-filings.  

Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) is the venture capital investment platform of Canopy Growth Corporation (TSX:WEED, NYSE:CGC).

Canopy Rivers is a unique investment and operating platform structured to pursue investment opportunities in the emerging global cannabis sector. Canopy Rivers collaborates with Canopy Growth to identify strategic counterparties seeking financial and/or operating support. Headquartered in Toronto, Canada, Canopy Rivers has developed an ecosystem of complementary cannabis operating companies operating throughout the cannabis value chain.

Canopy Rivers, in collaboration with Canopy Growth, has established a diverse portfolio of cannabis industry investments that includes domestic and international companies, licensed producers, late-stage licensed producer applicants, pharmaceutical formulators, brand developers and distributors, retail networks, and technology and media platforms. Investments are customized for each counterparty and include a balanced mix of equity, debt, royalty and profit-sharing agreements.

Canopy Rivers’ expanding portfolio includes:

  • Agripharm Corp. (private) is an ACMPR licensed producer, acquired by Canopy Growth in January 2017. In November 2017 Agripharm completed a joint venture with globally recognized partners Green House Seeds and Organa Brands. Canopy Growth has sublicensed proprietary technology, trademarks, genetics, know-how and other intellectual property from Agripharm to distribute the suite of Green House and Organa Brands products across the country, when permissible.
  • CanapaR Corp. (private) owns 80% of CanapaR Italy, a Sicily-based company focused on developing and commercializing Italy’s local hemp cultivation industry through its partnership with the renowned Department of Agriculture at the University of Catania and its rapidly building extraction capabilities for the production of organic CBD oil. CanapaR Italy’s outsource farming model with local Sicilian farmers and its university partnership will provide it with a low-cost source of organic CBD oil, which is increasingly used as an input into new commercial products in the growing health and wellness industries.
  • Civilized Worldwide Inc. (private), is a media and lifestyle brand with offices in New Brunswick and California that embraces and highlights modern cannabis culture. Civilized aims to engage the millions of productive, motivated people who choose to enjoy cannabis responsibly as part of their lifestyle. Reaching 2+ million unique visitors per month, North America-wide, Civilized produces engaging content for and about people who enjoy cannabis responsibly.
  • James E. Wagner Cultivation Ltd. (TSXV:JWCA) was founded in 2007 by third generation agricultural and cannabis cultivators. JWC is the first entirely aeroponic producer of cannabis in Canada, and its patent-pending aeroponic production technology, called GrowthStormTM, allows for perpetual harvesting and improved yields. The company was issued a license to cultivate from Health Canada in January 2017 and a subsequent sales license in March 2018.
  • LiveWell Foods Canada Inc. (TSXV:LVWL) was established in 1993 as a nutritional lifestyle company, and operates in the production of fresh produce and food technology. The company’s O-Hemp division distributes bulk and retail hemp products through its existing channel partners. LiveWell entered into a strategic agreement with Canopy Rivers and Canopy Growth in April 2018.
  • PharmHouse (private) is a joint venture between Canopy Rivers and the principals and operators of leading North American greenhouse produce companies. PharmHouse has arranged to acquire a newly built 1.3-million-square-foot greenhouse located in Leamington, Ontario.
  • Radicle Cannabis Inc. (private) is an ACMPR-licensed cannabis company based in Hamilton, Ontario backed by a management team that brings extensive experience in regulated industries, retail distribution, tobacco and pharmaceutical development, as well as Award-winning cannabis horticulturist breeders and medical professionals.
  • Solo Growth (TSXV:ALZ) is a new cannabis retail concept that will operate locations under the name “YSS by Solo,” relying on the expertise of a management team comprised of founding shareholders, senior officers and board members of Solo Liquor Stores Ltd., a leading Canadian liquor retailer. Solo Growth was established through a recapitalization of Aldershot Resources Ltd.’s corporate structure that will allow the company to execute a new retail-focused cannabis business strategy.
  • Spot Therapeutics Inc. (private) is an applicant that was acquired by Canopy Growth in August 2017 to solidify its Maritimes expansion strategy and less than four weeks later Canopy Growth signed a supply MOU with the New Brunswick government. Canopy Rivers purchased the property and entered into a long-term lease and committed funding agreement with Canopy Growth.
  • TerrAscend Corp. (CSE:TER) cultivates high-quality cannabis in an indoor hydroponic facility, backed by a strategic investor boasting a strong background in the pharmaceutical space and an extensive portfolio of specialty pharma assets.
  • Vert Mirabel (private) is a joint venture that was established in December 2017 between Canopy Rivers, Canopy Growth, and Les Serres Stephane Bertrand. Bertrand is a large-scale greenhouse operator located in Mirabel, Quebec, and the largest grower of pink tomatoes in the country. With guidance and assistance from Canopy Growth, the greenhouse has been upgraded and retrofitted for cannabis production and was licensed by Health Canada in May 2018.

As the company’s portfolio continues to develop, each constituent benefits from opportunities to collaborate with Canopy Growth and among themselves. Canopy Rivers believes this formula results in an ideal environment for innovation, synergy and value creation for Canopy Rivers, Canopy Growth and across the entire Rivers ecosystem.

Canopy Rivers is led by an experienced team of qualified financial and technical professionals with deep industry experience and relationship networks. The company’s acting CEO and chairman is Bruce Linton, CEO of Canopy Growth and founder of Tweed Marijuana.

Canopy Rivers Inc. (CNPOF), closed Friday's trading session at $0.9872, off by 5.981%, on 88,637 volume with 149 trades. The average volume for the last 3 months is 125,766 and the stock's 52-week low/high is $0.779999971/$4.7800002.

Recent News

chart

OriginClear (OTC: OCLN)

The QualityStocks Daily Newsletter would like to spotlight OriginClear (OTC: OCLN).

OriginClear (OTCQB: OCLN), a leading provider of water treatment solutions, was featured on this week’s episode of MoneyTV with Donald Baillargeon. To view the full press release, visit http://nnw.fm/U5tUj.

OriginClear (OTC: OCLN) leads the self-reliant water revolution, deploying advanced technologies at the point of use, with modular, prefabricated systems that create durable assets and water independence for industry, commerce and agriculture.

Failing infrastructure and the rising cost of water are driving businesses to treat their own water. OriginClear leads this megatrend with on-premise systems enabling very high purification and recycling levels that centralized systems cannot achieve.

Systems installed at the point of use become productive assets for businesses that also increase property values. And OriginClear helps corporations improve their environmental, social and governance (ESG) standings with world-class water management.

Operations & Markets

OriginClear leads a new generation of water companies that focus on meeting the needs of businesses looking for compact, advanced technologies that can be shipped to and installed at the point of use. The company manufactures and distributes its professional-grade water treatment and conveyance products to commercial and industrial properties, fielding both direct and indirect sales channels to reach end-market clients such as hotels and resorts, real estate housing developments, office buildings, military installations, schools, farms, food and beverage manufacturers, industrial warehouse, oil and gas producers, and medical and pharmaceutical facilities.

From its Texas-based factory, OriginClear designs and prefabricates an entire line of plug-n-play containerized units called Modular Water Systems™ that enable water purification, recycling and wastewater management.


Industrial Pretreatment Waste Water Treatment Plant (WWTP) designed by Daniel M. Early, using reinforced thermoplastic modules.

These onsite modular products provide clients with water independence through ownership and operational control over water quality, enabling them to increase productivity while reducing environmental, health and safety risks from pollution, contamination and corrosion. Modular water products are trusted to balance performance with cost-effectiveness, enabling business users to go well beyond municipal standards for water quality, therefore achieving high levels of satisfaction for their own customers, and improved sustainability for their properties.

OriginClear’s water treatment equipment can boost real estate asset value as a fundamental capital improvement, combined with long-lasting water savings for the corporate bottom line.

Product Portfolio

OriginClear groups its products into three main categories:

  1. Water Treatment: achieving high grade purification.
  2. Water Conveyance: water transportation and pumping.
  3. Advanced Technologies: commercialization of innovative technologies.

OriginClear’s complete line of compact, on-site, point-of-use products include: advanced purification systems that are skid, rack-mounted and containerized for reverse osmosis, ultrafiltration, media filtration, disinfection, water softening, ion exchange and electrodeionization (EDI), combined as needed in small to medium commercial and industrial applications, and custom-build projects. Water conveyance products include pump and lifting stations, modular storage tanks, and control monitoring panels.

OriginClear’s line of modular water products and systems is key to the self-reliant water treatment revolution as they create “instant infrastructure” – fully engineered, prefabricated and prepackaged systems that use durable, sophisticated materials. The units are available in standard capacities for onsite closed-loop systems at commercial business locations.

The company’s rugged wastewater treatment plants, highly reliable pump stations, and premium water purification units typically offer 25 percent lower initial costs over conventional systems, with greater quality and full connectivity. These pump stations and wastewater treatment products utilize high density thermo-plastics (HDPE) and proprietary, innovative prefabrication methods and materials that deliver the longest life and strongest products.

Breakthrough Technologies

OriginClear has a long history of innovation through its OriginClear Technologies division, which is responsible for identifying leading-edge technologies to solve today’s toughest challenges. These advanced technologies are the centerpiece of the division’s international licensee network. The technologies are developed in OriginClear Technologies, and licensees integrate them into their own products.

Electro Water Separation™ (EWS) and Advanced Oxidation (AOx™) are the principal, well-proven technologies.

EWS is OriginClear’s breakthrough water cleanup technology which utilizes a catalytic process to concentrate and eliminate suspended solids in the worst commercial and industrial wastewater.

AOx is OriginClear’s proprietary advanced oxidation technology which generates a dense cloud of ozone, hydrogen peroxide and hydroxyl radicals, dramatically reducing or eliminating dissolved organic microtoxins, including bacteria and viruses, hormones, drugs, pesticides such as Roundup, and synthetics. AOx has also been shown to effectively reduce harmful chemicals such as ammonia and hydrogen sulfide – the “rotten egg” smell in crude oil that reduces its value.

Through international licensing and partnerships, OriginClear’s advanced technologies are being adopted to treat tough water problems in East and South Asia, Europe and the Middle East, and North America.

Market Opportunity

In just 10 years, the global water services market has doubled into a trillion-dollar industry, driven by improper sanitation and water scarcity. Only 20 percent of all sewage and only 30 percent of all industrial waste are ever treated. Additionally, water leakage results in the loss of 35 percent of all clean water across the planet; reducing that percentage by half would provide clean water for 100 million people. This is a situation of great danger, but also great potential.

The statistics demonstrate that we can no longer rely on the efficiencies of giant, centralized water utilities to meet these challenges. An increasing number of businesses are starting to take notice, instead conducting their own water treatment and recycling. Whether by choice or out of necessity, those businesses that do invest in onsite water systems get a tangible asset on their business and real estate, and can enjoy better water quality at a lower cost.

Out of the public’s eye and with OriginClear’s help, a growing number of self-reliant businesses are building Decentralized Water Wealth™ for themselves while also helping their community. They know that environmental, social and governance (ESG) investing guidelines, which represent $22 trillion of assets under management around the world, specifically note the key indicator of how well corporations manage their water.


10,000 Gallon per Day Industrial Membrane Bioreactor Waste Water Treatment Plant designed by Daniel M. Early, PE, using long-lived Structural Reinforced ThermoPlastic (SRTP)

OriginClear is a key enabler of ESG water management for corporations that are increasingly responsible for what was once delegated to central utilities. For example, when a corporation manages its own water, and uses OriginClear’s proprietary hybrid treatment methods, it can significantly reduce both water use and nutrient footprints (carbon, nitrogen, and phosphorus) in one compact package.

These hybrid processes feature advanced blackwater treatment with advanced clean water processing. They can convert toxic nutrients to less harmful compounds, and even capture them for beneficial reuse purposes, as shown in OriginClear’s recent case study.

Revenue Growth through Synergy

Since OriginClear acquired it in 2015, Progressive Water Treatment has generated steady revenues in the range of a million dollars a quarter. It is now the Fabrication and Manufacturing Division for the whole company. The team at Modular Water Systems, headed by Chief Engineer Daniel M. Early, is responsible for overall design and high-level engineering. It relies on the Fabrication and Manufacturing Division to add incremental revenue for its modular product line, without requiring large increases in personnel.

OriginClear believes that these two business units can develop growing revenues through synergy and ultimately help achieve overall profitability. OriginClear also seeks to acquire profitable water companies that can complement the synergy of its existing units and accelerate both revenues and profitability. However, acquisitions are neither guaranteed, nor essential to OriginClear’s continued growth.

 

Leadership

OriginClear’s management team brings strong leadership and a background in managing business operations, sales, technologies, and finance. The team combines idealism with solid commercial skills, achieving a triple bottom line of environmental, social and financial gain.

Riggs Eckelberry – Chairman, CEO and Co-founder
Riggs Eckelberry is a veteran technology manager who led companies to multiple exits during the high-tech boom of the 90s and early 2000s. Eckelberry came to the water industry from a quarter century in high technology, specializing in commercializing breakthrough technologies. During the dotcom boom, he worked on a series of tech successes, such as Quarterdeck’s CleanSweep; security software vendor Panda Software; and the sale of companies to EarthWeb, BeFree, and BellSouth. Just prior to founding what is now OriginClear, he helped drive security software company CyberDefender to an IPO on the Nasdaq as its president and chief operating officer.

Thomas Marchesello – Chief Operating Officer
Thomas Marchesello is a business operations and technology executive with over 20 years’ experience in manufacturing and distribution of products and services. He has 12 years in private equity M&A, doing buyside acquisitions of small to midsize corporations. He has over 10 years advising innovative corporations on ESG strategy and speaks often about industry trends. He began his career in the U.S. Air Force, Space Command Headquarters for environmental sciences. He has held key roles for Fortune 500 companies such as Sony, Thompson Reuters, Morgan Stanley, and Chicago Mercantile Exchange.

Daniel M. Early, PE – Senior Engineer
For the past 25 years, Dan Early has worked as an engineered products development specialist with very strong understanding of the complex and interconnected disciplines, economies, and governmental regulation needed to develop and sustain modern civil infrastructure systems that reflect a balance of environmental stewardship, social expectations, and cultural requirements. Since 2010, Early has specialized in the research, development, and deployment of next generation water infrastructure technologies using heavy plastic manufacturing. His initiatives and innovations anchor Modular Water Systems’ product line.

Marc Stevens – Director of Fabrication and Manufacturing
Marc Stevens brings nearly 40 years of experience to OriginClear’s manufacturing team. His experience in mechanical design, equipment fabrication, installation and a wide range of projects led to his founding what is now OriginClear’s Fabrication and Manufacturing Division. He supervises the design, building and installation of customized, large-scale water treatment systems, including purification technologies for process waters for boilers and cooling towers, drinking water and various industrial waste water applications. Stevens leads the team that also manufactures OriginClear’s standardized Modular Water Systems.

OriginClear (OCLN), closed Friday's trading session at $0.1061, off by 9.7021%, on 114,669 volume with 42 trades. The average volume for the last 3 months is 75,343 and the stock's 52-week low/high is $0.078749999/$5.80000019.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower

ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.